BioMarin ’s Next Roctavian Challenge Is How To Successfully Commercialize Its Gene Therapy: Warranties May Be An Option

As BioMarin turns to commercialization of Roctavian, we will likely hear more about how warranties could help gene therapies overcome payer reimbursement hurdles.

Source: Forbes.com Healthcare News - July 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news